Clinical Trials
235 trialsImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
panSOHO
Bayer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
OMNIRAY
Eli Lilly and Company
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
TTBF
University of California, San Francisco
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
SERPENTINE
Vall d'Hebron Institute of Oncology
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shenzhen Ionova Life Sciences Co., Ltd.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
RAD301
Radiopharm Theranostics, Ltd
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech SE
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
AH-HA
Wake Forest University Health Sciences
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
PRESERVE-009
OncoC4, Inc.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences